ADC Therapeutics develops cancer treatments, led by ZYNLONTA for certain lymphomas, and is based in Epalinges, Switzerland. ADCT reports earnings on Tue, Nov 10, 2026.
Prices, price targets and earnings estimates for ADCT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in ADCT in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADCT is in one of them and how their past ADCT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About ADC Therapeutics SA
ADC Therapeutics is a biopharmaceutical company based in Epalinges, Switzerland. It develops cancer treatments built on antibody drug conjugates, which link an antibody that targets cancer cells to a cell-killing payload. Its main product is ZYNLONTA, used for a type of lymphoma that has returned or stopped responding to earlier treatment, and partner Sobi handles much of its commercialization. Its customers include patients, the doctors who treat them, and the insurers and government programs that pay for care.
